All lobbying filings
JAZZ PHARMACEUTICALS, INC.
JAZZ PHARMACEUTICALS, INC. filed a Q4 report for JAZZ PHARMACEUTICALS, INC. on January 16, 2026.
Lobbying for JAZZ PHARMACEUTICALS, INC.
Filing · LD-2 quarterly report
Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 16, 2026
Expenses
$490,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
California
Government bodies contacted
5
Lobbying activity
1
FDA regulation of CBD FDA Rare Disease PPRV program/reauthorization Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Most Favored Nation drug pricing Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act HR 946: Orphan Cures Act
Bills named in this filing
1